Telomerase inhibition, oligonucleotides, and clinical trials.
about
Therapeutic Targeting of TelomeraseTherapeutic targeting of replicative immortalityEffects of allicin on both telomerase activity and apoptosis in gastric cancer SGC-7901 cells.Antisense oligonucleotides and all-trans retinoic acid have a synergistic anti-tumor effect on oral squamous cell carcinoma.Expression of (NES-)hTERT in cancer cells delays cell cycle progression and increases sensitivity to genotoxic stressAnalysis of a long-range interaction between conserved domains of human telomerase RNA.Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo.Telomere biology of pediatric cancer.Telomere dynamics: the means to an end.MicroRNAs as targets for antisense-based therapeutics.Targeting telomerase in hematologic malignancy.PML body meets telomere: the beginning of an ALTernate ending?Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation.Biochemical properties of Trypanosoma cruzi telomerase.Efficient inhibition of human telomerase activity by antisense oligonucleotides sensitizes cancer cells to radiotherapy.Effects of phosphorothioate anti-sense oligodeoxynucleotides on colorectal cancer cell growth and telomerase activityInhibition of telomerase activity by HDV ribozyme in cancersAminoglycoside-quinacridine conjugates: towards recognition of the P6.1 element of telomerase RNA.N-(1-Pyrenyl) maleimide inhibits telomerase activity in a cell free system and induces apoptosis in Jurkat cells.
P2860
Q26741736-A6391DD9-4607-48C5-B0A4-7ACCB405F049Q27027457-5354398A-BE9D-4BA1-A646-79F0C6E9FCD5Q31156804-90771CEF-2289-46B0-ABC9-B5AEF8773B02Q33340152-B978E2A4-D078-4234-941E-A4B2AB92ADAAQ33593132-13F7534F-0926-4530-B9D4-1BCB95CBB3A1Q34365513-11C38DE2-E21A-4E67-B562-BD749C8B95DBQ36438203-690BB6B3-F279-495F-92E7-D73DF7BA86BCQ36832376-548B81DE-A86C-4F7E-BE4C-49E365C878A3Q36884191-1595ADA4-106B-4E0F-ACF1-A436BA7616F9Q37032639-A0BEBE7E-2722-414C-B873-3B98BA455E64Q37750789-56927A63-9CBC-4330-A4C4-2085DD94AF55Q38008909-3796DB9D-9ACF-46D0-9A2F-99E249C0415BQ38304986-38B2DBD1-1731-4D56-9452-101CE93F917AQ40157259-A8FC41C3-488A-4909-832F-4C8DB1ED1B97Q40241243-47280497-E837-445B-B1B8-7F31FA700166Q40495946-3C066752-CC16-4D9A-BDBC-7E4FF53E70B1Q41821170-46FBF7A2-BD52-44D5-B082-08C7BD38101FQ46891246-266013D5-9E6B-4CF6-9A13-4DBDA1F9736EQ54503717-A291DE89-9DE9-4C5D-A804-B184BA5F9C7F
P2860
Telomerase inhibition, oligonucleotides, and clinical trials.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Telomerase inhibition, oligonucleotides, and clinical trials.
@ast
Telomerase inhibition, oligonucleotides, and clinical trials.
@en
Telomerase inhibition, oligonucleotides, and clinical trials.
@nl
type
label
Telomerase inhibition, oligonucleotides, and clinical trials.
@ast
Telomerase inhibition, oligonucleotides, and clinical trials.
@en
Telomerase inhibition, oligonucleotides, and clinical trials.
@nl
prefLabel
Telomerase inhibition, oligonucleotides, and clinical trials.
@ast
Telomerase inhibition, oligonucleotides, and clinical trials.
@en
Telomerase inhibition, oligonucleotides, and clinical trials.
@nl
P2860
P356
P1433
P1476
Telomerase inhibition, oligonucleotides, and clinical trials.
@en
P2093
David R Corey
P2860
P2888
P304
P356
10.1038/SJ.ONC.1205063
P407
P577
2002-01-01T00:00:00Z
P5875
P6179
1004844132